lower schreef op 28 februari 2018 16:24:
BioCryst commences long-term safety study of BCX7353 in HAE patients; shares up 2%
Feb. 28, 2018 10:18 AM ET|About: BioCryst Pharmaceutica... (BCRX)|By: Douglas W. House, SA News Editor
Dosing is underway in a long-term safety trial, APeX-S, assessing BioCryst Pharmaceuticals' (BCRX +1.7%) BCX7353 as a preventative treatment in patients with hereditary angioedema (HAE). The open-label two-arm study will evaluate the safety of two dose levels (110 mg and 150 mg once daily) over 48 weeks in ~160 patients with Type I and Type II HAE.
The results will supplement the efficacy and safety data generated in the Phase 3 APeX-2 study that will commence shortly.